Potential Drug Target or Biomarker: PPIH (Small Nuclear Ribonucleoprotein Particle-Specific Cyclophilin H)

Target Name: PPIH

NCBI ID: G10465

PPIH

Potential Drug Target or Biomarker: PPIH (Small Nuclear Ribonucleoprotein Particle-Specific Cyclophilin H)

Introduction

PPIH (Small Nuclear Ribonucleoprotein Particle-Specific Cyclophilin H) is a protein that has been identified as a potential drug target or biomarker. It is a key regulator of cell proliferation and has been linked to various diseases, including cancer. This article will explore the biology of PPIH, its potential as a drug target, and its potential as a biomarker for various diseases.

Biochemistry and Structure

PPIH is a 22-kDa protein that is expressed in various tissues and cells. It is a member of the cyclophilin family, which includes proteins that regulate protein synthesis and degradation. PPIH is specific to the nuclear envelope and is involved in the regulation of nuclear import and export.

PPIH has a characteristic cyclophilin-like structure, with a long amino acid sequence that includes a cyclic dinucleotide repeat and a hydrophobic tail. It has been shown to interact with various nuclear proteins, including importin and exportin, which are involved in the import and export of proteins into the nucleus.

Function and Druggability

The function of PPIH is not well understood, but it is involved in the regulation of various cellular processes, including cell proliferation, apoptosis, and transcriptional regulation. PPIH has been shown to play a role in the regulation of cell cycle progression, and it has been linked to the maintenance of the G1 phase of cell growth.

As a drug target, PPIH is potentially targeted by small molecule inhibitors that can inhibit its function. Cyclophilins are known to be responsive to small molecules, and several inhibitors have been shown to be effective in inhibiting their activity. PPIH may also be targeted by inhibitors of its downstream regulators, such as the DNA damage-inducible kinase (DDI-K) and the Ku70 gene.

PPIH is also a potential biomarker for various diseases, including cancer. The expression of PPIH has been observed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, PPIH has been shown to be involved in the regulation of cellular processes that are altered in cancer, such as cell adhesion and migration.

Conclusion

PPIH is a protein that has potential as a drug target or biomarker. Its unique structure and function, as well as its involvement in various cellular processes, make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the biology of PPIH and its potential as a drug and biomarker.

Protein Name: Peptidylprolyl Isomerase H

Functions: PPIase that catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and may therefore assist protein folding (PubMed:20676357). Participates in pre-mRNA splicing. May play a role in the assembly of the U4/U5/U6 tri-snRNP complex, one of the building blocks of the spliceosome. May act as a chaperone

The "PPIH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets